Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants.

Scientific reports - 17 Jun 2021

Tanaka Shiho, Nelson Gard, Olson C Anders, Buzko Oleksandr, Higashide Wendy, Shin Annie, Gonzalez Marcos, Taft Justin, Patel Roosheel, Buta Sofija, Richardson Ashley, Bogunovic Dusan, Spilman Patricia, Niazi Kayvan, Rabizadeh Shahrooz, Soon-Shiong Patrick

Abstract excerpt

The SARS-CoV-2 variants replacing the first wave strain pose an increased threat by their potential ability to escape pre-existing humoral protection. An angiotensin converting enzyme 2 (ACE2) decoy that competes with endogenous ACE2 for binding of the SARS-CoV-2 spike receptor binding domain (S RBD) and inhibits infection may offer a therapeutic option with sustained efficacy against variants. Here, we used...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Molecular Dynamics Simulation

Share to Protein Domains

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 34140558
DOI: 10.1038/s41598-021-91809-9
PMCID: PMC8211782

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants.PMID 34140558Read ↗

A recombinant ‘ACE2 Triple Decoy’ that traps and neutralizes SARS-CoV-2 shows enhanced affinity for highly transmissible SARS-CoV-2 variantsSemantic proximity Read ↗

A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.Semantic proximity Read ↗

ACE2-based decoy receptors for SARS coronavirus 2.Semantic proximity Read ↗

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read ↗

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.Semantic proximity Read ↗

David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitorsSemantic proximity Read ↗

Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variantsSemantic proximity Read ↗

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2Semantic proximity Read ↗

Computational and Experimental Identification of Potential Neutralizing Peptides Derived from Human ACE2 Against SARS-CoV-2 InfectionSemantic proximity Read ↗

Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variantsSemantic proximity Read ↗

A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivoSemantic proximity Read ↗

Molecular Insights into the Variability in Infection and Immune Evasion Capabilities of SARS-CoV-2 Variants: A Sequence and Structural Investigation of the RBD Domain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.